Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 7.1% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health Inc. (HIMS) offers a range of health and wellness products and FDA-approved medications for various conditions. Recently, its stock faced significant downward movement.

Why is Hims & Hers Health Inc. going down?

HIMS stock is down 7.1% on Mar 12, 2026 14:45

• The end of a partnership with Novo Nordisk, a securities class action lawsuit, and accusations of violating laws related to mass sales of compounded drugs and deceptive marketing are believed to have influenced the decline in HIMS stock.
• Although HIMS resolved the partnership issue with Novo Nordisk to provide branded obesity drugs, ongoing uncertainties and potential near-term margin challenges, as pointed out by Morningstar, may have impacted investor confidence.
• Real-time signal analysis suggesting increased downside risk and Novo Nordisk's decision to sell its weight-loss drug through the telehealth platform might have contributed to the negative market sentiment surrounding HIMS.
• Investors could be reacting to the changes in supply and regulatory requirements resulting from the shift to branded therapies from compounded alternatives, affecting Hims & Hers Health's investment outlook and possibly raising concerns about its future performance.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS

Kahn Swick & Foti, LLC (KSF) has launched an investigation into Hims & Hers Health, Inc. (HIMS) and its officers and directors following the termination of a partnership with Novo Nordisk and a securities class action lawsuit. Novo Nordisk accused Hims & Hers of violating laws against mass sales of compounded drugs and disseminating deceptive marketing. KSF's investigation will focus on whether fiduciary duties were breached or laws violated, inviting shareholders with information to contact them.

https://www.businesswire.com/news/home/20260309690198/en/Hims-Hers-Health-Investigation-Initiated-Kahn-Swick-Foti-LLC-Investigates-the-Officers-and-Directors-of-Hims-Hers-Health-Inc.---HIMS

Hims & Hers: Repartnering With Novo Removes Legal Overhang and Reshapes Weight Loss Segment

Hims & Hers has re-partnered with Novo Nordisk to sell Novo’s FDA-approved diabetes and obesity treatments, leading to the dismissal of Novo’s patent infringement lawsuit and a 40% jump in Hims shares. While the legal overhang is removed, Morningstar maintains its $23 fair value estimate for Hims due to lingering uncertainties and potential near-term margin weakness despite a forecasted slight increase in revenue for the weight-loss segment. Hims will shift from advertising compounded GLP-1 medications to promoting FDA-approved versions, though a limited number of customers may still access compounded drugs.

https://www.morningstar.com/stocks/hims-hers-repartnering-with-novo-removes-legal-overhang-reshapes-weight-loss-segment

Why Hims & Hers Health (HIMS) Is Up 8.4% After Novo Nordisk GLP-1 Partnership Resolution – And What's Next

Hims & Hers Health (HIMS) saw an 8.4% increase after resolving a legal dispute with Novo Nordisk and entering a partnership to offer branded GLP-1 obesity drugs like Wegovy and Ozempic. This shift from compounded alternatives to branded therapies will impact Hims & Hers Health's investment narrative, reducing legal risks but introducing new supply and regulatory dependencies. The company's 2026 revenue guidance remains to be fully reconciled with this new agreement, and analysts show varying long-term projections.

https://www.sahmcapital.com/news/content/why-hims-hers-health-hims-is-up-84-after-novo-nordisk-glp-1-partnership-resolution-and-whats-next-2026-03-08

Avoiding Lag: Real-Time Signals in (HIMS) Movement

This article provides real-time signal analysis for Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting a near-term strong sentiment challenging persistent mid and long-term weakness. It identifies elevated downside risk due to a lack of long-term support signals and presents three distinct AI-generated trading strategies tailored to different risk profiles. The analysis includes multi-timeframe signal strength, support, and resistance levels for HIMS.

https://news.stocktradersdaily.com/news_release/12/Avoiding_Lag:_Real-Time_Signals_in_HIMS_Movement_030826092402_1772976242.html

Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report

Novo Nordisk and Hims & Hers Health Inc. have reportedly settled their legal dispute, with Novo Nordisk agreeing to sell its weight-loss drug on the telehealth platform. This partnership comes despite a previous feud and lawsuit over Hims & Hers marketing a compounded version of Novo Nordisk's drug. The deal signals a shift in strategy for Novo Nordisk amid growing competition in the weight-loss drug market.

https://www.sahmcapital.com/news/content/novo-nordisk-and-hims-hers-end-bitter-legal-feud-with-surprise-weight-loss-drug-deal-report-2026-03-07

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 7.5% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.5% Today

Aave ($AAVE) Crypto Forecast: Up 5.3% Today

PancakeSwap ($CAKE) Crypto Forecast: Up 5.3% Today

Hims & Hers Health Inc. Price History

05.02.2026 - HIMS Stock was down 5.3%

• The decline in HIMS stock is linked to uncertainties surrounding its U.S. endeavors, notably in the high-risk GLP-1 sector that faces regulatory and legal challenges, including disputes with Novo Nordisk.
• Analysts are apprehensive about the potential impacts of regulatory scrutiny, rising operational expenses, and forthcoming FDA regulatory modifications on HIMS's profitability, possibly contributing to the bearish trend in the stock market.
• Ongoing litigation with Novo Nordisk relating to patent violations and allegedly misleading marketing assertions has added another layer of complexity and difficulty for Hims & Hers Health, diminishing investor trust and fueling the downward market trend.

10.02.2026 - HIMS Stock was up 6.1%

• The positive news of the company re-partnering with Novo Nordisk to sell FDA-approved diabetes and obesity treatments led to the dismissal of a patent infringement lawsuit and a significant rise in Hims shares.
• Despite potential near-term margin weakness, the shift from advertising compounded GLP-1 medications to promoting FDA-approved versions likely boosted investor confidence in the company's future prospects.
• Bullish options activity and varied analyst opinions, with a consensus target price of $30.1, reflect optimism and interest in Hims & Hers Health's potential growth trajectory.

13.01.2026 - HIMS Stock was up 6.0%

• The regulatory scrutiny and legal challenges faced by HIMS regarding its weight-loss pill could have initially caused a decline in the stock price.
• However, the strong bullish movement today suggests that investors may be optimistic about the company's ability to navigate these challenges and find a resolution.
• The FDA's crackdown on HIMS could potentially benefit competitors like Novo Nordisk and Eli Lilly, who have been losing market share to compounded alternatives.
• The uncertainty surrounding HIMS' future growth strategy and the impact of regulatory actions on its GLP-1 offerings may continue to influence the stock's performance in the near future.

24.01.2026 - HIMS Stock was down 6.5%

• The bearish movement in HIMS stock can be attributed to the negative news surrounding the company's sale of unapproved GLP-1 weight loss drugs sourced from a questionable supplier, raising concerns about regulatory scrutiny and potential legal liabilities.
• Additionally, the ongoing fraud investigation by the Schall Law Firm into potential securities law violations further added to investor unease, leading to a significant drop in the stock price.
• Despite the positive news of Hims & Hers' acquisition of Eucalyptus to expand its digital health footprint, the overshadowing negative developments regarding regulatory compliance and legal risks seem to have dominated investor sentiment, resulting in the bearish market movement for HIMS.

26.01.2026 - HIMS Stock was down 5.5%

• Analysis suggests weak sentiment and heightened downside risk, potentially leading investors to lean towards a short bias.
• Concerns were raised about the sale of unapproved weight loss drugs from an undisclosed supplier, sparking fears of regulatory intervention and impacting investor confidence.
• Scrutiny over Hims' prescription procedures and the use of drugs from a supplier with a history of fraud may have cast doubt on the company's compliance with regulations and standards, affecting investor sentiment.
• The stock decline and undervaluation indications from P/E ratio analysis could have influenced the bearish trend as investors reevaluated the company's prospects in light of these issues.

04.02.2026 - HIMS Stock was up 6.0%

• The bullish market movement of HIMS today may be linked to positive trade ideas shared by analysts on TradingView, emphasizing the company's strong fundamentals, growth in telemedicine, and subscription model.
• Initially, a legal dispute with Novo Nordisk might have caused some uncertainty; however, HIMS's resilience and strategic decisions, including withdrawing the contentious product, likely reassured investors and contributed to the bullish trend.
• Despite investor concerns about margin compression and slower earnings growth, the Q4 and full-year revenue figures may have bolstered market confidence, fueling the stock's upward trend.

02.02.2026 - HIMS Stock was up 5.4%

• The positive movement in HIMS stock today can be linked to various factors:
• Analysts' optimistic projections based on technical patterns including cup and handle formations and symmetrical triangles, indicating favorable momentum.
• Despite worries about margin compression and slower earnings growth, investors hold a positive view on the company's solid fundamentals, expansion in telemedicine, and subscription approach.
• The company's lower P/E ratio compared to the industry norm suggests potential undervaluation, which is attracting value-focused investors.
• Overall, there is a sense of optimism in the market regarding HIMS's future growth opportunities, despite encountering some hurdles in its financial performance.

12.02.2026 - HIMS Stock was down 7.1%

• The end of a partnership with Novo Nordisk, a securities class action lawsuit, and accusations of violating laws related to mass sales of compounded drugs and deceptive marketing are believed to have influenced the decline in HIMS stock.
• Although HIMS resolved the partnership issue with Novo Nordisk to provide branded obesity drugs, ongoing uncertainties and potential near-term margin challenges, as pointed out by Morningstar, may have impacted investor confidence.
• Real-time signal analysis suggesting increased downside risk and Novo Nordisk's decision to sell its weight-loss drug through the telehealth platform might have contributed to the negative market sentiment surrounding HIMS.
• Investors could be reacting to the changes in supply and regulatory requirements resulting from the shift to branded therapies from compounded alternatives, affecting Hims & Hers Health's investment outlook and possibly raising concerns about its future performance.

17.01.2026 - HIMS Stock was down 5.2%

• AI models have indicated a bearish sentiment across various timeframes for HIMS stock, suggesting a preference for short positions and highlighting increased downside risk.
• Despite experiencing notable declines in its share price over the past month and year, the elevated price-to-earnings (P/E) ratio of 29.3x, surpassing the market average, may have dissuaded investors seeking more attractive investment opportunities.
• While analysts have projected robust annual earnings growth of 21% for HIMS in the future, concerns stemming from the high P/E ratio overshadowed these forecasts. Consequently, investors engaged in a sell-off as they reassessed their positions in light of the company's performance prospects.

11.02.2026 - HIMS Stock was up 5.9%

• The bullish movement in HIMS stock can be attributed to the positive news of the re-partnership between Hims & Hers and Novo Nordisk to sell FDA-approved diabetes and obesity treatments. This move not only resolves the legal overhang from the patent infringement lawsuit but also opens up new revenue streams for HIMS.
• The settlement of the legal dispute and the agreement to sell Novo Nordisk's weight-loss drug on the telehealth platform indicates a strategic shift for both companies, which has likely boosted investor confidence in the potential growth prospects for HIMS.
• The real-time signal analysis highlighting a strong sentiment in the near term and the elevated downside risk due to a lack of long-term support signals may have also contributed to increased trading activity and buying interest in HIMS stock.

10.01.2026 - HIMS Stock was up 7.5%

• HIMS stock experienced a positive trend today despite the regulatory and legal issues linked to its compounded semaglutide weight-loss pill.
• The release of a $49 compounded version of Novo Nordisk's Wegovy by Hims & Hers has disrupted the obesity drug market, creating uncertainties in regulations and posing threats to the dominant position of major pharmaceutical companies.
• A legal battle with Novo Nordisk over allegations of unauthorized mass compounding of oral semaglutide by Hims & Hers has raised concerns about patient safety and intellectual property, impacting investor confidence and pricing strategies in the competitive weight loss drug sector.
• Despite facing regulatory and legal obstacles, investors appear hopeful about the future of HIMS stock, potentially influenced by market expectations or anticipated developments in the company's growth strategy.

09.01.2026 - HIMS Stock was up 6.1%

• HIMS stock saw a bullish movement following the strategic launch of a lower-priced compounded oral semaglutide treatment plan, disrupting market dynamics.
• The competition with Novo Nordisk's Wegovy pill has raised legal concerns and triggered potential regulatory scrutiny, indicating a bold market entry by Hims & Hers.
• Analysts predict potential legal and regulatory challenges due to the perceived grey area of legality surrounding the compounded drug, introducing risk and uncertainty to HIMS's market position.
• Overall sentiment analysis and institutional trading strategies indicate a short bias, yet the market has positively responded to the company's move, leading to a bullish movement in HIMS stock.